Opko Health Inc. (OQ:OPK)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd
MIAMI FL 33137-3212
Tel: 1-212-8383777
Website: www.opko.com
IR: See website
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President
Jon Roger Cohen
Executive Chairman of BioReference Laboratories
Geoff Monk
President of BioReference
Steven D. Rubin
Executive Vice President - Administration, Director
Business Overview
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Financial Overview
For the fiscal year ended 31 December 2018, Opko Health Inc. revenues increased 3% to $990.3M. Net loss decreased 50% to $153M. Revenues reflect Diagnostics segment increase of 4% to $813.2M, Mexico segment increase of 22% to $5.6M, Ireland segment increase of 1% to $78.1M. Lower net loss reflects Diagnostics segment loss decrease of 67% to $44.9M, Corporate segment loss decrease of 22% to $43.6M.
Employees: 5,690 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $1,674M as of Dec 31, 2018
Annual revenue (TTM): $990.27M as of Dec 31, 2018
EBITDA (TTM): -$47.17M as of Dec 31, 2018
Net annual income (TTM): -$153.04M as of Dec 31, 2018
Free cash flow (TTM): -$137.00M as of Dec 31, 2018
Net Debt Last Fiscal Year: $116.99M as of Dec 31, 2018
Shares outstanding: 615,600,775 as of Feb 15, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization